Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Company moves away from manual processing in favour of automated, scalable platforms.

As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

Ryan Cawood, CEO, Oxford Genetics said: “This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations. We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.

“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.

“We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry.”

Headquartered in Oxford, UK, Oxford Genetics is a leading synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry. The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.